Multi-omics analysis of inflammatory bowel disease

Immunology Letters

Volumn 162, Issue 2, 2014, Pages 62-68

  Huang, Hu ^a   Vangay, Pajau ^a   McKinlay, Christopher E ^a   Knights, Dan ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b University of Minnesota   (United States)

Author keywords

Bioinformatics; Inflammatory bowel diseases; Machine learning; Metagenomics; Microbiome; Multi omics

Indexed keywords

ANIMAL; BIOLOGY; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; MICROBIOLOGY; MICROFLORA; MUCOSAL IMMUNITY; PHYSIOLOGY;

ANIMALS; COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MICROBIOTA;

EID: 84914154556     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.07.014     Document Type: Review

References (86)

1. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
2. Khor B., Gardet A., Xavier R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011, 474:307-317.
3. Fiocchi C. Towards a 'cure' for IBD. Dig Dis 2012, 30:428-433.
4. Weinstock J.V., Elliott D.E. Helminths and the IBD hygiene hypothesis. Inflamm Bowel Dis 2009, 15:128-133.
5. Yadav S.P. The wholeness in suffix -omics, -omes, and the Word Om. J Biomol Tech 2007, 18:277.
6. Ishii N., Tomita M. Multi-omics data-driven systems biology of E. coli. Systems biology and biotechnology of Escherichia coli 2009, 41-57. Springer, Dordrecht, Netherlands. S.Y. Lee (Ed.).
7. Zhang W., Li F., Nie L. Integrating multiple 'omics' analysis for microbial biology: application and methodologies. Microbiol 2010, 156:287-301.
8. Jostins L., Ripke S., Weersma R.K., Duerr R.H., McGovern D.P., Hui K.Y., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-124.
9. Thompson A.I., Lees C.W. Genetics of ulcerative colitis. Inflamm Bowel Dis 2011, 17:831-848.
10. Anderson C.A., Boucher G., Lees C.W., Franke A., D'Amato M., Taylor K.D., et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011, 43:246-252.
11. Franke A., McGovern D.P.B., Barrett J.C., Wang K., Radford-Smith G.L., Ahmad T., et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010, 42:1118-1125.
12. Baur P., Gruber L., Bosco N., Brahmbhatt V., Collino S., Guy P., et al. Metabolic phenotyping of the Crohn' s disease-like IBD etiopathology in the TNF (δARE/WT) mouse model. J Proteome Res 2011, 10:5523-5535.
13. Wirtz S., Neurath M.F. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007, 59:1073-1083.
14. Sugimoto K., Ogawa A., Mizoguchi E., Shimomura Y., Andoh A., Bhan A.K., et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008, 118:534-544.
15. Gophna U., Sommerfeld K., Gophna S., Doolittle W.F., Veldhuyzen van Zanten S.J.O. Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis. J Clin Microbiol 2006, 44:4136-4141.
16. Bibiloni R., Mangold M., Madsen K.L., Fedorak R.N., Tannock G.W. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J Med Microbiol 2006, 55:1141-1149.
17. Peterson D.A., Frank D.N., Pace N.R., Gordon J.I. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe 2008, 3:417-427.
18. Lepage P., Häsler R., Spehlmann M.E., Rehman A., Zvirbliene A., Begun A., et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterol 2011, 141:227-236.
19. Westermann A., Gorski S., Vogel J. Dual RNA-seq of pathogen and host. Nat Rev Microbiol 2012, 10:618-630.
20. Erickson A.R., Cantarel B.L., Lamendella R., Darzi Y., Mongodin E.F., Pan C., et al. Integrated metagenomics/metaproteomics reveals human host-microbiota signatures of Crohn's disease. PLOS ONE 2012, 7:e49138.
21. Hugot J., Chamaillard M., Zouali H., Lesage S., Ce J., Macry J. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
22. Ogura Y., Bonen D., Inohara N., Nicolae D. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
23. Ogura Y., Inohara N., Benito A., Chen F.F., Yamaoka S., Nunez G. NOD2, a NOD1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001, 276:4812-4818.
24. Knights D., Lassen K.G., Xavier R.J. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 2013, 62(10):1505-1510.
25. Horak C.E., Snyder M. Global analysis of gene expression in yeast. Funct Integr Genomics 2002, 2:171-180.
26. Ye R.W., Wang T., Bedzyk L., Croker K.M. Applications of DNA microarrays in microbial systems. J Microbiol Methods 2001, 47:257-272.
27. Kok K., Stokkers P., Reitsma P. Genomics and proteomics. Implications for inflammatory bowel diseases. Inflamm Bowel Dis 2004, 10:1-6.
28. Hermeking H. Serial analysis of gene expression and cancer. Curr Opin Oncol 2003, 15:44-49.
29. Wang Z., Gerstein M., Snyder M. RNA-seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009, 10:57-63.
30. Costello C.M., Mah N., Häsler R., Rosenstiel P., Waetzig G.H., Hahn A., et al. Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med 2005, 2:e199.
31. Carey R., Jurickova I., Ballard E., Bonkowski E., Han X., Xu H., et al. Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:446-457.
32. Marlow G., Ellett S., Ferguson I.R., Zhu S., Karunasinghe N., Jesuthasan A.C., et al. Transcriptomics to study the effect of a Mediterranean-inspired diet on inflammation in Crohn's disease patients. Hum Genomics 2013, 7:24.
33. Lin J., Welker N.C., Zhao Z., Li Y., Zhang J., Reuss S.A., et al. Novel specific microRNA biomarkers in idiopathic inflammatory bowel disease unrelated to disease activity. Mod Pathol 2014, 27:602-608.
34. de Bruyn M., Machiels K., Vandooren J., Lemmens B., Van Lommel L., Breynaert C., et al. Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease. Inflamm Bowel Dis 2014, 20:339-352.
35. Clark P.M., Dawany N., Dampier W., Byers S.W., Pestell R.G., Tozeren A. Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning targets for IBD and other autoimmune diseases. Inflamm Bowel Dis 2012, 18:2315-2333.
36. Wu F., Guo N., Tian H. Peripheral blood microRNAs distinguish active ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2011, 17:241-250.
37. Pandey A., Mann M. Proteomics to study genes and genomes. Nature 2000, 405:837-846.
38. Mann M., Jensen O. Proteomic analysis of post-translational modifications. Nat Biotechnol 2003, 21:255-261.
39. Bennike T., Birkelund S., Stensballe A., Andersen V. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. World J Gastroenterol 2014, 20:3231-3244.
40. Ong S.E., Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 2005, 1:252-262.
41. Aebersold R., Mann M. Mass spectrometry-based proteomics. Nature 2003, 422:198-207.
42. Alex P., Gucek M., Li X. Applications of proteomics in the study of inflammatory bowel diseases. Inflamm Bowel Dis 2009, 15:616-629.
43. Chaerkady R., Pandey A. Applications of proteomics to lab diagnosis. Annu Rev Pathol 2008, 3:485-498.
44. Barceló-Batllori S., André M., Servis C. Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases. Proteomics 2002, 2:551-560.
45. Fogt F., Jian B., Krieg R.C., Wellmann A. Proteomic analysis of mucosal preparations from patients with ulcerative colitis. Mol Med Rep 2008, 1:51-54.
46. May D., Pan S., Crispin D. Investigating neoplastic progression of ulcerative colitis with label-free comparative proteomics. J Proteome Res 2010, 10:200-209.
47. Meuwis M.A., Fillet M., Geurts P., de Seny D., Lutteri L., Chapelle J.P., et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Parmacol 2007, 73:1422-1433.
48. Seeley E.H., Washington M.K., Caprioli R.M., M'Koma A.E. Proteomic patterns of colonic mucosal tissues delineate Crohn's colitis and ulcerative colitis. Proteomics Clin Appl 2013, 7:542-549.
49. Roda G., Caponi A., Sartini A., Cevenini M., Colliva C., Roda A. Update on current applications of proteomic in the study of inflammatory bowel disease. Ann Gastroenterol 2012, 25:303-308.
50. Patti G.J., Yanes O., Siuzdak G. Innovation Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 2012, 13:263-269.
51. Marchesi J., Holmes E. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 2007, 6:546-551.
52. Marchesi J.R., Holmes E., Khan F., Kochhar S., Scanlan P., Shanahan F., et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 2007, 6:546-551.
53. Jansson J., Willing B., Lucio M., Fekete A., Dicksved J., Halfvarson J., et al. Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS ONE 2009, 4:e6386.
54. Baur P., Martin F.P., Gruber L., Bosco N., Brahmbhatt V., Collino S., et al. Metabolic phenotyping of the Crohn's disease-like IBD etiopathology in the TNF(δARE/WT) mouse model. J Proteome Res 2011, 10:5523-5535.
55. Le Gall G., Noor S.O., Ridgway K., Scovell L., Jamieson C., Johnson I.T., et al. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. J Protemoe Res 2011, 10:4208-4218.
56. Williams H.R.T., Willsmore J.D., Cox I.J., Walker D.G., Cobbold J.F.L., Taylor-Robinson S.D., et al. Serum metabolic profiling in inflammatory bowel disease. Dig Dis Sci 2012, 57:2157-2165.
57. Hisamatsu T., Okamoto S., Hashimoto M., Muramatsu T., Andou A., Uo M., et al. Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease. PLOS ONE 2012, 7:e31131.
58. 1H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. J Proteome Res 2012, 11:3344-3357.
59. Ooi M., Nishiumi S., Yoshie T., Shiomi Y., Kohashi M., Fukunaga K., et al. GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Infamm Res 2011, 60:831-840.
60. Bjerrum J.T., Nielsen O.H., Hao F., Tang H., Nicholson J.K., Wang Y., et al. Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteome Res 2010, 9:954-962.
61. Sharma U., Singh R.R., Ahuja V., Makharia G.K., Jagannathan N.R. Similarity in the metabolic profile in macroscopically involved and un-involved colonic mucosa in patients with inflammatory bowel disease: an in vitro proton ((1)H) MR spectroscopy study. Magn Reson Imaging 2010, 28:1022-1029.
62. Balasubramanian K., Kumar S., Singh R.R., Sharma U., Ahuja V., Makharia G.K., et al. Metabolism of the colonic mucosa in patients with inflammatory bowel diseases: an in vitro proton magnetic resonance spectroscopy study. Magn Reson Imaging 2009, 27:79-86.
63. Williams H.R.T., Cox I.J., Walker D.G., North B.V., Patel V.M., Marshall S.E., et al. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J Gastroenterol 2009, 104:1435-1444.
64. Stephens N.S., Siffledeen J., Su X., Murdoch T.B., Fedorak R.N., Slupsky C.M. Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy. J Crohns Colitis 2013, 7:e42-e48.
65. Storr M., Vogel H.J., Schicho R. Metabolomics: is it useful for inflammatory bowel diseases. Curr Opin Gastroenterol 2013, 29:378-383.
66. Huttenhower C., Gevers D., Knight R., Abubucker S., Badger J.H., Chinwalla A.T., et al. Structure, function and diversity of the healthy human microbiome. Nature 2012, 486:207-214.
67. Kanehisa M., Goto S., Sato Y., Furumichi M., Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 2012, 40:109-114.
68. Langille M.G.I., Zaneveld J., Caporaso J.G., McDonald D., Knights D., Reyes J.A., et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 2013, 31:814-821.
69. Betteridge J.D., Armbruster S.P., Maydonovitch C., Veerappan G.R. Inflammatory bowel disease prevalence by age, gender, race, and geographic location in the U.S. military health care population. Inflamm Bowel Dis 2013, 19:1421-1427.
70. Morgan X.C., Tickle T.L., Sokol H., Gevers D., Devaney K.L., Ward D.V., et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012, 13:R79.
71. Jernberg C., Löfmark S., Edlund C., Jansson J.K. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 2007, 1:56-66.
72. Dethlefsen L., Relman D.A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. PNAS 2011, 108:4554-4561.
73. Sokol H., Seksik P. The intestinal microbiota in inflammatory bowel diseases: time to connect with the host. Curr Opin Gastroenterol 2010, 26:327-331.
74. Pérez-Cobas A.E., Artacho A., Knecht H., Ferrús M.L., Friedrichs A., Ott S.J., et al. Differential effects of antibiotic therapy on the structure and function of human gut microbiota. PLOS ONE 2013, 8:e80201.
75. David L.A., Maurice C.F., Carmody R.N., Gootenberg D.B., Button J.E., Wolfe B.E., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2013, 505:559-563.
76. Wu G.D., Chen J., Hoffmann C., Bittinger K., Chen Y.Y., Keilbaugh S.A., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011, 334:105-108.
77. Russell S., Norvig P., Canny J., Malik J., Edwards D. Artificial intelligence: a modern approach 1995, Prentice-Hall, Egnlewood Cliffs.
78. Higuera C., Pajares G., Tamames J., Morán F. Expert system for clustering prokaryotic species by their metabolic features. Expert Syst Appl 2013, 40:6185-6194.
79. Seto E., Leonard K.J., Cafazzo J.A., Barnsley J., Masino C., Ross H.J. Developing healthcare rule-based expert systems: case study of a heart failure telemonitoring system. Int J Med Inform 2012, 81:556-565.
80. Muthukaruppan S., Er M.J. A hybrid particle swarm optimization based fuzzy expert system for the diagnosis of coronary artery disease. Expert Syst Appl 2012, 39:11657-11665.
81. Lee K., Lee S. A causal knowledge-based expert system for planning an Internet-based stock trading system. Expert Syst Appl 2012, 39:8626-8635.
82. Knights D., Lassen K.G., Xavier R.J. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 2013, 62:1505-1510.
83. Tyler A.D., Milgrom R., Stempak J.M., Xu W., Brumell J.H., Muise A.M., et al. The NOD2insC polymorphism is associated with worse outcome following ileal pouch-anal anastomosis for ulcerative colitis. Gut 2013, 62:1433-1439.
84. Sehgal R., Berg A., Hegarty J.P., Kelly A.A., Lin Z., Poritz L.S., et al. NOD2/CARD15 mutations correlate with severe pouchitis after ileal pouch-anal anastomosis. Dis Colon Rectum 2010, 53:1487-1494.
85. NCBI PubMed database 2009, US National Library of Medicine, Bethesda, MD, Available from: https://www.ncbi.nlm.nih.gov/pubmed [cited 07.02.14].
86. Antonopoulos D.A., Huse S.M., Morrison H.G., Schmidt T.M., Sogin M.L., Young V.B. Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect Immun 2009, 77:2367-2375.